Podcasts about Melanoma

New York state prosecutors say they will reopen a criminal inquiry into the alleged rape of a woman at Cornell University in 2024. The woman, referred to in court documents as Jane Doe, alleges in her lawsuit that seven men from Cornell's Chi Phi fraternity chapter assaulted her in an incident involving alcohol and the drug ketamine. The case was investigated by university police but will now go before a grand jury. The case has been discussed widely online, with many including actress Florence Pugh reacting with fury over the reported disciplinary actions taken by the university. Nada Tawfik, BBC North American correspondent, and Tracey Vitchers, Executive Director of It's On Us, a non-profit programme dedicated to college sexual assault prevention, join Anita Rani to discuss.The broadcaster, campaigner and charity founder Dame Esther Rantzen has died at the age of 86. She will be best remembered for presenting the BBC TV Programme That's Life. She also set up Childline – the telephone helpline for children suffering abuse or neglect – and spent a lot of time campaigning for older people and for assisted dying. Guardian journalist Zoe Williams remembers her and her impact on women's lives. Australia has launched its Endometriosis Management Plan, which gives GPs and patients a much greater role in the management of their endo. Professor Danielle Mazza from Monash University in Melbourne has been instrumental in designing and delivering the plan. She discusses how the UK might benefit from something like this with Dr Sylvia Kama-Kieghe, a GP in Sheffield, and Vice President of Membership and Workforce at the College of Sexual and Reproductive Healthcare.A social media-driven resurgence in the popularity of sunbeds is said to be fuelling a rise in cases of skin cancer, particularly among young people, according to some experts. Melanoma, the most serious form of skin cancer, is now one of the most common cancers in people aged 15 to 34, according to Cancer Research UK. Meanwhile research by the Teenage Cancer Trust found around 48% of 18 to 34-year-olds in the UK use sunbeds – the highest proportion of any age group. Observer journalist Marine Saint has been looking into this, along with Rosie Vare from the Teenage Cancer Trust.Producer: Melanie Abbott Presenter: Anita Rani

Send us Fan MailWhat do you do when you've spent your life building businesses—and suddenly, you're told you may have only weeks to live?In this episode of the Today is the Day Changemakers podcast, host Jodi Hope Grinwald welcomes entrepreneurs and Smilo Foundation co-founders Mike and Bethany Smilovich for a deeply personal conversation about cancer, advocacy, partnership, and finding hope when the future feels uncertain.Mike's business experience spans healthcare, wellness, and consumer brands, including European Wax Center franchise locations, VIO Med Spa, and Bang Cookies. But a stage 4 melanoma diagnosis brought an entirely different challenge into his and Bethany's lives as parents of two young children.Mike was also diagnosed with leptomeningeal disease, which they describe as cancer spreading into his cerebrospinal fluid—the fluid surrounding the brain and spinal cord. During the interview, they recount being told that the average lifespan associated with his prognosis was eight weeks.Bethany stepped into the role of caregiver and advocate, researching treatment options, seeking additional opinions, and connecting with doctors and scientists. Together, they describe navigating major medical institutions, gathering information, and bringing what they learned back to Mike's care team.Their search eventually took them to Germany for T-cell therapy. Mike and Bethany share their experience with that treatment, the results they reported at the time of our conversation, and the questions they continued to explore.Throughout their journey, hope gave them motivation to take the next step. Hearing stories of people who had survived difficult diagnoses helped them believe other possibilities existed—and encouraged them to keep reaching out, learning, and asking questions.Their experience also revealed how difficult it can be to find relevant treatment information, even with resources, business experience, and an extensive network. That realization helped inspire the Smilo Foundation.Through the foundation, Mike and Bethany are working to connect patients and caregivers with information about cancer research, treatment options, and advocacy resources. They also discuss their plans for Smilo Compass, a tool intended to help patients identify potential treatment options to discuss with their doctors, with expert human review included in the process.This conversation explores the connections between entrepreneurship and advocacy, the emotional realities of caregiving, raising young children through uncertainty, and creating a mission to help others from a life-changing personal experience.Learn more about the Smilo Foundation, its mission, and opportunities to support its work:smilofoundation.orgFollow the foundation on Instagram: @thesmilofoundationPlease share this episode with someone who would value hearing Mike and Bethany's story. Their discussion reflects their personal experience; treatment decisions should be made with your medical care team.ABOUT TODAY IS THE DAYThe Today is the Day Changemakers podcast features conversations with changemakers, inspirers, and people disrupting the status quo in the best way possible. With more than 200 episodes and downloads in 143 countries and territories and over 1,400 cities, the podcast brings together voices whose experiences encourage us to think differently, connect more deeply, and take action.Host Jodi Hope Grinwald is the founder of Today is the Day LLC and creator of Connection Is the Work™. Through coaching, consulting, speaking, and training, she helps leaders, teams, and organizations strengthen connection and create sustainable growth.EXPLORE LIVE IT!Jodi's book, LIVE IT! — Edge of Comfort to Center of Impact, brings together 31 voices sharing experiences and perspectives on moving beyond comfort and creating impact. Learn more about the book and Jodi's work at todayisthedayliveit.com.STAY CONNECTEDSubscribe to Today is the Day Changemakers on YouTube and follow the podcast on your favorite listening platform.Follow Jodi on Facebook and Instagram: @todayisthedayliveitFacebook: facebook.com/todayisthedayliveitInstagram: instagram.com/todayisthedayliveitWebsite: todayisthedayliveit.comToday is the day. You cannot go back to yesterday, and you do not yet own tomorrow. What small or large step will you take today to get closer to your goal?#entrepreneur #cancersurvivor #melanoma #BangCookies #wellness #medspa #nonprofit #cure #changemakers #todayisthedaySupport the show

Is this mole something to worry about? Surgical oncologist, Taranjit Arora, M.D., explains how clinicians use the ABCDEs and “evolution” to flag suspicious lesions. She discusses symptoms that raise concern (itching, spontaneous bleeding), common biopsy methods (punch and shave), the role of dermatology and pathology in diagnosis, and why a changing lesion deserves prompt evaluation.

Marta García Aller ha conversado con Enrique Grande, jefe de servicio de oncología médica de Ruber Internacional Quiron Salud y Miguel Ángel Berciano, oncólogo médico e investigador en el Instituto de Investigación Biomédica de Málaga para conocer más de cerca los últimos avances en la investigación contra el cáncer.

Cancer cells do not grow in isolation. Their ability to survive and form tumors depends partly on how they interact with immune cells in the surrounding tumor microenvironment. Melanoma is particularly responsive to immune-based mechanisms, making it important to understand the molecular processes that allow melanoma cells to limit or escape antitumor immune responses. A research paper published in Volume 17 of Oncotarget, titled “DHHC3 interferes with antitumor immunity in melanoma cells,” investigated the role of the protein acyltransferase DHHC3 in melanoma growth, oxidative stress, cellular senescence, and antitumor immunity. Why Study DHHC3 in Melanoma? DHHC3 is one of 23 members of the DHHC family of protein acyltransferases. These enzymes modify proteins through a process known as palmitoylation, which can influence where proteins are located within cells and how they function. Previous research from the investigators showed that DHHC3 palmitoylates numerous antioxidant and redox-regulatory proteins, providing a mechanism through which it helps control intracellular oxidative stress. Higher DHHC3 expression has also been associated with poorer survival across several cancer types, while DHHC3 ablation has previously been shown to reduce breast tumor growth. However, an important question remained unresolved: does eliminating DHHC3 suppress tumors because of changes occurring directly within cancer cells, or because those changes allow the immune system to attack the tumor more effectively? Full blog post - https://www.oncotarget.org/2026/09/23/dhhc3-helps-melanoma-tumors-evade-antitumor-immunity/ DOI - https://doi.org/10.18632/oncotarget.28880 Correspondence to - Martin E. Hemler - martin_hemler@dfci.harvard.edu, and Chandan Sharma - csharma@mgh.harvard.edu Abstract video - https://www.youtube.com/watch?v=QQhP2VhzKSE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28880 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oxidative stress, DHHC3, anti-cancer immunity, palmitoylation, melanoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

SPONSORS: 1) AMENTARA: Head to www.amentara.com/go/JULIAN & use code JDP22 for 22% off your FIRST order. JOIN PATREON FOR EARLY UNCENSORED EPISODE RELEASES: https://www.patreon.com/JulianDorey CLIPPERS DISCORD: https://discord.gg/8QmWEKJ3BT NEWSLETTER: https://juliandoreypodcast.beehiiv.com/get-julians-top-10-books (***TIMESTAMPS in Description Below) ~ Dr. Abud Bakri, MD is a board-certified Internal Medicine physician, health educator, and medical consultant specializing in metabolic health, longevity, and clinical peptide therapies. He gained mainstream recognition as a leading expert on the biochemistry, safety, and regulation of experimental and therapeutic peptides. ABUD'S LINKS: - WEBSITE: https://abudbakri.com/ - IG: https://www.instagram.com/abud_bakri/?hl=en - X: https://x.com/AbudBakri FOLLOW JULIAN DOREY IG: https://www.instagram.com/julianddorey/ X: https://x.com/juliandorey JULIAN YT CHANNELS - SUBSCRIBE to Julian Dorey Clips YT: https://www.youtube.com/@juliandoreyclips - SUBSCRIBE to Julian Dorey Daily YT: https://www.youtube.com/@JulianDoreyDaily - SUBSCRIBE to Best of JDP: https://www.youtube.com/@bestofJDP ****TIMESTAMPS**** 0:00 - Dr. Abud, Gaza & "Medicine Lost Its Soul" 10:29 - Twelve Minutes: How Little Doctors See You 20:20 - COVID, the Thymus & Weakened Immunity 30:10 - Zinc, T Cells & Blue Zones Debunked 41:35 - Why mRNA Trust Broke Down 51:00 - Peptides Explained, Insulin in 1922 1:01:22 - GLP-1's Origin: Lizard Venom 1:10:15 - Pharma's New Target: Healthy People 1:20:00 - Sunlight, Melanoma & Cancer as Immune Escape 1:32:00 - BPC-157 and the Growth Hormone Debate 1:44:40 - Pill Mills & the Peptide Community 1:47:57 - GLP-1s, Dopamine & AI Horror Stories 1:59:30 - Why We Should Love the Sun 2:07:49 - Russian Peptides & Vladimir Khavinson's Death 2:20:14 - Epitalon & Soviet Research Lost 2:32:15 - Circadian Rhythm & Vegas Casino Design 2:42:47 - Black Market Peptides & Research Grade 3:00:22 - Where Medicine Goes in Ten Years 3:03:07 - Abud's Work CREDITS: - Host, Editor & Producer: Julian Dorey - COO, Producer & Editor: Alessi Allaman - https://www.youtube.com/@UCyLKzv5fKxGmVQg3cMJJzyQ - In-Studio Producer: Joey Deef Julian Dorey Podcast Episode 479 - Abud Bakri Music by Artlist.io Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode, Josh and Michael examine the treatment of advanced melanoma, the condition that blazed the trail for immunotherapy to change the face of cancer treatment. However, immunotherapy is not the ONLY treatment for melanoma, as a significant proportion of cases also harbour a BRAF mutation. So, if you have someone with such an example, what do you do? How would you sequence your treatment? This question, and a reflection on the incredible beginnings of immunotherapy is coming to you on today's episode.Studies Discussed in Today's EpisodeCheckmate 067DreamSeqFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Elsa Ludwig, DVM, PhD, MS, CVA, DACVS (LA), joined us to talk about melanoma in horses and a new technology she has been using to treat skin tumors called H-FIRE.This episode of Disease Du Jour is brought to you by Bimeda.GUESTS AND LINKS - EPISODE 190:Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Elsa Ludwig, DVM, PhD, MS, CVA, DACVS (LA)Podcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Bimeda.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

In this episode, Elsa Ludwig, DVM, PhD, MS, CVA, DACVS (LA), joined us to talk about melanoma in horses and a new technology she has been using to treat skin tumors called H-FIRE.This episode of Disease Du Jour is brought to you by Bimeda.GUESTS AND LINKS - EPISODE 190:Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Elsa Ludwig, DVM, PhD, MS, CVA, DACVS (LA)Podcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Bimeda.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

Protect the Skin you're In! September is all about Skin-Care & Self-Care. In this episode Jenny D. interviews Leah Adams-Kretschmar, a melanoma survivor who recounts her diagnosis at 26, her father's experience, treatment, and the emotional journey afterward. They discuss tanning risks, sun safety, UPF clothing, sunscreen choices, genetic risk factors, immunotherapy advances, and the mental health impact of a cancer diagnosis. Leah emphasizes the importance of regular skin checks, early detection, and practical prevention tips to protect your skin year-round. Leah's quote "Cancer gets a chapter...It doesn't get the whole damn story:" September Spotlight Supporter is Seraly Dermatology located in McMurray, Pa.  This month is all about SkinCare & SelfCare.  Seraly focuses on Skin Wellness for your family!  Call today to make an appointment. 724-969-2500 https://www.drmarkseraly.com/ All episodes are available on all the major Audio Platforms as well as Jenny D's YouTube page. Make sure to Subscribe and Follow. http://www.youtube.com/@Spillwithmejennyd Note: Jenny D. is now recording at StudioMe Productions. Please check out her YouTube Video. If you would like to be a guest or sponsor on Spill with Me Jenny D. Show please fill out the disclaimer at https://www.spillwithmejennyd.com/tell-your-story or email spillwithmejennyd@gmail.com Don't Forget to Subscribe & Follow. Thank you to our Community Partners! Note: "The views and conversations in this podcast are intended solely for informational and educational purposes. They do not constitute professional advice, and listeners are encouraged to seek their own guidance for any specific concerns." "Music Credit: Theme song, written and performed by Mark Ferrari"    markferrarimusic.com      

A new mRNA vaccine for advanced melanoma is generating significant interest, but what does it actually mean for patients? In the latest episode of Life by a Thousand Cuts, A/Prof Tony Dicker examines the recent trial of Moderna's personalised mRNA vaccine, intismeran, in combination with pembrolizumab. He explains how the treatment is designed around the individual mutations in a patient's melanoma, the early evidence for improved recurrence-free survival, and some of the practical challenges involved in producing a personalised vaccine. For GPs, the key distinction is that this is not a vaccine to prevent melanoma. Rather, it is an emerging treatment approach for patients who already have advanced melanoma, and one that patients may increasingly ask about as more results receive media attention. Prefer a visual format? Watch this podcast here.   Next steps in your learning journey

Drs. Maura Di Nicola and Basil Williams join to discuss the September 2026 edition of Retinal Physician found online at http://www.retinalphysician.com. Topics focus on ocular oncology and uveitis.

Dr. Jedd Wolchok, a pioneer in melanoma research, joins Dr. Monty Pal to break down practice-changing advances in the field, including landmark 10-year CheckMate-067 survival data, safer immunotherapy dosing, and the rise of neoadjuvant treatment. LINK TO FULL TRANSCRIPT  

This week I'm joined by Dr Michael, dermatologist and skin cancer specialist, and someone who has dedicated his career to changing the way we understand sun, skin and one of the most preventable yet misunderstood cancers in the world.We explore sunscreen, UV exposure, vitamin D, skin cancer and what you actually need to know to protect yourself and the people you love.Dr Michael is a board-certified dermatologist specialising in skin cancer prevention, diagnosis and treatment. He is on a mission to reframe how we think about sun exposure and sunscreen, cutting through the noise to give people genuinely actionable, evidence-based guidance. He sees the consequences of sun damage and late stage skin cancer diagnoses every day and believes that with the right information, most of it is preventable.What we explore together:•The truth about sunscreen — is it actually good for you or are we getting it wrong•Why most people are applying sunscreen incorrectly and what the right amount actually looks like•The sunscreen and vitamin D debate and what the science really says•Why darker skin tones are more at risk of vitamin D deficiency and what to do about it•When you should be getting skin checks and what to look for yourself•How quickly skin cancer can progress and what the warning signs are•What the latest research says about sunscreen chemicals and whether they are harmfulLove, Sarah Ann

In this episode, Michael and Josh delve into the world of early melanoma. Some may think that melanoma has had its moment in the sun (pun slightly intended) and that other cancer treatments are passing it by. But in this instance, you can teach an old dog new tricks, an old immunotherapy dog, to be precise. In addition, one of today's studies has Michael's favourite design of any trial: see if you can figure out which one!Studies Discussed in Today's EpisodeKEYNOTE-054NADINAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

A new mRNA vaccine for melanoma is making headlines. Moderna and Merck recently announced results from their clinical trial suggesting that this new vaccine, in combination with the cancer drug Keytruda, reduced recurrence rates in patients. The companies have not yet released full data from the trial. So, how does the vaccine work? And does this mark the beginning of a new era of cancer treatments using mRNA vaccine technology? Ira talks with physician Michael Postow, whose patients were part of the drug trial at Memorial Sloan Kettering Cancer Center. Guest: Dr. Michael Postow is chief of the melanoma service at Memorial Sloan Kettering Cancer Center. Transcript will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In Milwaukie you can migrate to 1847 Taphouse and enjoy over 30 taps, 11 food carts, and sunny patio. Ryan Kiernan from Truck Melanoma is handing out sunscreen and raising awareness. Beer buyer Tyler Wood has the deets on the best menu picks and upcoming events. Josh gets wild about Kolschfest at Mayfly, and Damian finds a dark treat on draft. Sun and fun on a 3rd floor sky lounge on this episode of Brew Happy!

Missed your weekly dose of women’s health headlines? Dr Ginni Mansberg and Cath Mahoney are breaking down the biggest health news, from a groundbreaking cancer-hunting virus offering new hope for melanoma, to reassuring research for expectant mothers on antidepressant safety.They also unpack the viral "dopamine menu" trend: can non-screen mood boosters really reset your brain, or is it just another social media gimmick? In Are You Well? Dr Ginni breaks down major upcoming changes to breast cancer screening in Australia, plus the red flags to watch for to protect yourself from fake medical practitioners. And in Asking for a Friend, we tackle your awkward anonymous questions. This week, we're answering whether Friday night wine is driving your restless legs, what’s really behind incomplete bowel movements, and why olive oil might be the ultimate wiping hack. Leave us an 'Asking for a Friend' voice note here. Follow us on Instagram and Tiktok. Very Peri, Mamamia's exclusive perimenopause series is here! 25 world-leading experts, over 20 on-demand sessions, instant access. We’ve sorted through the noise so you don't have to. Go to veryperi.com.au today. You hot? Same. CREDITS Hosts: Dr Ginni Mansberg & Cath Mahoney Senior Producer: Tina Matolov Executive Producer: Courtney Ammenhauser Audio Producer: Scott Stronach Social Media Producer: Zara Meier Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on. Information discussed in Well. is for educational purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional. Right now, every Mamamia subscriber is automatically entered to win a $5,000 Dreamworld holiday for four; flights, accommodation, express passes and more included. Subscribe here to enter. T&Cs apply. Become a Mamamia subscriber and get an all-access pass to everything we make, including exclusive podcasts and early listening, subscriber-only articles, monthly giveaways and our home workout app, MOVE. Get access to Very Peri, Mamamia's exclusive perimenopause series, for just $59. 25 world-leading experts, over 20 on-demand sessions, available now. We’ve sorted through the noise so you don't have to. Go to veryperi.com.au today. You hot? Same.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

In this episode of What's Up, Doc? on the Eye Believe Podcast, we sit down with Dr. Omid Hamid, Chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute and Co-Director of its Melanoma and Phase I Programs. A recognized leader in melanoma and immuno-oncology, Dr. Hamid discusses the evolving treatment landscape for ocular melanoma, the growing number of clinical trials and treatment options, and why collaboration and patient choice are so important. He also shares his excitement about where research is headed and his hope for a future where physicians have many more options to offer their patients. Then we go beyond the white coat. Get to know Dr. Hamid as he talks about his family, what keeps him motivated through difficult days, his newfound attempt at finding Zen through golf, his love of travel and movies, and even what's on his playlist. Join us for a conversation about innovation, patient care, and the person behind the physician. Learn more about A Cure In Sight: https://acureinsight.org Thank you to our sponsors for making this possible! Ideaya Biosciences Delcath Systems Aura Biosciences Castle Biosciences Immunocore Natera Rare Cancer. Resilient Hope. Revolutionary Research. #OcularMelanoma #EyeBelievePodcast #WhatsUpDoc #OmidHamid #Immunotherapy #ClinicalTrials #RareCancer #ACureInSight

If you like cemiplimab, you will like this episode. Since its introduction, cemiplimab has become the mainstay of treatment for cutaneous SCC, the most common non-melanoma skin cancer likely to attend an oncologist. Cemiplimab's scope is expanding; once reserved purely for the locally advanced or metastatic setting, evidence is emerging for its efficacy in the neoadjuvant setting. Today, Josh and Michael explore the use cases for cemiplimab in cSCCNOTE: this episode was NOT sponsored by cemiplimab!Studies Discussed in Today's EpisodeMigden et al. (2018)Gross et al (2023)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Send Zorba a message!Zorba's thoughts on the groundbreaking mRNA therapeutic vaccine to combat melanoma.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba's thoughts on the groundbreaking mRNA therapeutic vaccine to combat melanoma.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

In today's episode, we spoke with Michael K. Wong, MD, PhD, FRPC. Dr Wong is a physician at Roswell Park Comprehensive Cancer Center in Buffalo, New York.In our exclusive interview, Dr Wong discussed the significance of the FDA's accelerated approval of vusolimogene oderparepvec-wtpg (Tudriqev; RP1) in combination with nivolumab (Opdivo) for adult patients with unresectable advanced cutaneous melanoma whose disease progressed on a prior PD-1–blocking antibody–based regimen. He noted that this approval followed a lengthy regulatory trajectory, including two prior complete response letters, before a third biologics license application was accepted in June 2026 and a positive advisory committee vote paved the way for approval.Dr Wong contextualized the evidentiary basis for the approval, drawing on data from the single-arm, phase 1/2 IGNYTE trial (NCT03767348), in which the efficacy-evaluable population achieved an objective response rate of 24.2% (95% CI, 15.8%-34.3%) and a median duration of response of 14.1 months (95% CI, 10.7-not reached). He emphasized that the trial enrolled a genuinely high-risk population, including patients with elevated lactate dehydrogenase, more than 55% with PD-L1–negative tumors by immunohistochemistry, 44% who had failed prior ipilimumab (Yervoy) plus nivolumab, and 66% with primary resistance to anti–PD-1 therapy, making the results clinically meaningful in the context of a setting where no robust options previously existed.  He also addressed the distinction between RP1 and talimogene laherparepvec (Imlygic), the prior herpes-based oncolytic agent, explaining that RP1 is a fundamentally reengineered particle with distinct genetic modifications, enhanced oncolytic activity, and an expanded injection approach that includes visceral lesions such as those in the liver and lung. From an operational standpoint, Dr Wong outlined key considerations for community and academic practices looking to integrate RP1, including room setup, pharmacy handling of live agents, personal protective equipment protocols, and the importance of partnering with interventional radiology to inject a diversity of lesions across nodal basins for optimal response.Finally, Dr Wong positioned RP1 plus nivolumab within the broader post–PD-1 treatment landscape alongside tumor-infiltrating lymphocyte (TIL) therapy, noting that although both options now occupy this space, RP1 plus nivolumab offers a more broadly accessible treatment approach given the logistical demands of TIL therapy. 

This episode highlights three clinically relevant developments: positive phase 3 results for individualized mRNA neoantigen therapy plus pembrolizumab after melanoma surgery, emerging MRI and AI approaches that may identify Alzheimer's-related brain changes years earlier, and substantial LDL-C treatment gaps under the 2026 ACC/AHA dyslipidemia guideline. Together, the findings underscore advances in precision oncology, early neurodegenerative risk detection, and cardiovascular prevention.

Moderna y Merck anunciaron resultados exitosos en los ensayos de la primera vacuna personalizada contra el melanoma, marcando un hito sin precedentes en la inmunoterapia del cáncer. Para entender el impacto científico y médico de este avance, Pablo Aranzaes conversa en #SonarInformativo con el Dr. Flavio Salazar, investigador biomédico en cáncer y académico de la Universidad de Chile. En la entrevista, el especialista detalla el funcionamiento de la tecnología de ARN mensajero aplicada a la oncología, el porcentaje de efectividad registrado en los pacientes y las perspectivas sobre cuándo esta vacuna podría estar disponible a nivel clínico global. Acompaña la conversación en Sonar Informativo para profundizar en la ciencia, la medicina preventiva y el futuro del tratamiento contra el cáncer de piel.

A personalised mRNA vaccine has shown promising early results in preventing high-risk melanoma from returning when combined with the immunotherapy drug Keytruda. Dr Heidi Hart explains how the treatment works, why the trial results are significant, and what still needs to happen before personalised cancer vaccines could become widely available. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

August 25, 2026 ~ Chris Renwick and Lloyd Jackson check in with Dr. Yusra Shao, Medical Oncologist, Karmanos Cancer Center, about a new vaccine to prevent melanoma. How does it work and how soon will this become widely available? Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

P.M. Edition for Aug. 24. Treasury Secretary Scott Bessent says the U.S. will go after countries and companies that do business with Iran. White House economic policy reporter Brian Schwartz says it's unclear what will happen with Iran's top trading partner: China. Plus, President Trump escalates the trade conflict with Canada, threatening 50% tariffs on autos. And Heard on the Street columnist David Wainer discusses the challenges Moderna faces in fulfilling investor hopes for a sweeping new era for cancer treatment. Pierre Bienaimé hosts. The AI Therapist: A WSJ Podcast Series  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Merck Moderna's success with a personalised cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumours. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up ‌the immune system, personalised cancer vaccines train the immune system to specifically target mutations found only on a person's tumour. To react to this development, Alan Morrissey spoke with Skin Cancer Survivor from Quin, Kate Moloney. Photo (c) Андрей Клеменков from Getty Images via Canva.com

On the heels of consequential primary race results, some of the big winners join the program. Plus, President Trump says that North Korea has 57 powerful nuclear weapons. Also, an experimental vaccine shows promising results for patients with melanoma.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

The world's okayest morning radio show offers you the entire broadcast from today with none of the music and limited commercials. Try to enjoy!

Esmeralda Ruiz entrevista a Marisol Soengas, jefa del grupo de melanoma del Centro Nacional de Investigaciones Oncológicas (CNIO).

Como as novas vacinas de mRNA contra o câncer, a revisão de protocolos em endocrinologia pediátrica e a vigilância em cardio-oncologia impactam a tomada de decisão médica? Neste episódio do Afya News, analisamos os resultados positivos de fase 3 da vacina personalizada de mRNA associada ao pembrolizumabe no tratamento adjuvante do melanoma ressecado. Discutimos também a nova diretriz da Endocrine Society que recomenda uma abordagem mais individualizada na puberdade precoce central, priorizando o LH basal e evitando investigações desnecessárias. Por fim, apresentamos no Radar as evidências sobre o uso de medicamentos cardioprotetores contra a cardiotoxicidade dos tratamentos oncológicos. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/20-08-2026Conteúdo 100% validado por equipe médica.Médico Responsável: Dr. Guilherme Rodrigues — CRM-RJ 1049461.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into recent strides made in scientific research, regulatory landscapes, and market dynamics that are shaping the future of healthcare. Starting with a significant breakthrough in cancer treatment, Merck & Co. and Moderna have reported promising results from their Phase 3 melanoma trial. Their investigational mRNA-based vaccine, intismeran autogene, when paired with Keytruda, has shown a substantial reduction in melanoma recurrence risk. This combination exemplifies the growing role of mRNA technology in oncology, moving beyond its initial success with infectious diseases. The synergy between mRNA platforms and immune checkpoint inhibitors like Keytruda underscores a pivotal shift in cancer therapeutics, potentially transforming treatment paradigms with more targeted and personalized approaches. On the regulatory front, Heidi Overton's nomination as the new FDA Commissioner marks a critical juncture for the agency. Her leadership could bring fresh perspectives to drug approval processes at a time when swift regulatory actions are essential to bring innovative therapies to market. This shift in FDA leadership is expected to influence the speed and efficiency with which new treatments reach patients, highlighting the agency's evolving role in balancing innovation with safety. In Singapore, GSK's Blenrep has received approval for use in combination therapies targeting relapsed or refractory multiple myeloma. This antibody-drug conjugate specifically targets the BCMA protein on myeloma cells, offering new hope for patients who have exhausted conventional treatment options. The approval exemplifies ongoing advancements in targeted therapies aimed at improving outcomes for complex cancers. The industry is also witnessing strategic collaborations that could reshape clinical trial access and efficiency. Merck & Co.'s partnership with Sarah Cannon Research Institute aims to enhance community-based oncology trials through the Accelero model, democratizing access to cutting-edge cancer therapies. By bringing trials closer to patients, this initiative could accelerate data collection and recruitment efforts, ultimately benefiting patient outcomes. In manufacturing advancements, Genprex's collaboration with an undisclosed CDMO to scale up its AAV-based diabetes gene therapy production is noteworthy. This partnership is crucial for advancing gene therapy solutions targeting chronic diseases like diabetes, offering potential long-term treatment efficacy through innovative therapeutic platforms. Financially, CSL has experienced a resurgence following increased demand for immunoglobulin products, resulting in stronger-than-expected revenue figures. This rebound highlights the resilience of plasma-derived therapies and signals growing market demand amid fluctuating global health challenges. PitchBook's prediction of a resurgence in biotech venture capital funding further underscores the sector's dynamic nature. This anticipated investment influx is likely to drive demand for CDMOs specializing in cell and gene therapy manufacturing over the next few quarters, reinforcing the industry's growth trajectory. In clinical trial news, Enveda's ENV-308 has successfully cleared its Phase 1 safety trial for obesity management by targeting appetite suppression pathways involving GLP-1 and lac-phe mechanisms. As it progresses to Phase 2 trials, this novel approach represents a significant advancement in addressing metabolic disorders through innovative therapeutic avenues. Conversely, regulatory setbacks continue to challenge manufacturers. Aurobindo's Eugia unit received an FDA warning letter over sterile manufacturing violations, emphasizing the importance of maintaining stringent quality standards within pharmaceutical production processes. Overall, these developments highlight a dynamic industry poised at the intersection of scientific innovation and regulatory evolution. The implications for patient care are profound as new therapies emerge with enhanced efficacy and safety profiles across various disease spectrums. Continuous collaboration between industry players and regulatory bodies remains vital to sustaining momentum and ensuring groundbreaking treatments efficiently reach those in need. That's it for today's briefing on Pharma Daily. Stay tuned as we continue to track these developments and more within this ever-evolving landscape of pharmaceutical and biotech industries. Stay informed and stay ahead!Support the show

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta quinta-feira (20/08/2026): As farmacêuticas Moderna e Merck anunciaram que uma vacina terapêutica experimental de mRNA permitiu que pessoas com melanoma de alto risco tivessem uma sobrevida maior, livres do câncer. Os laboratórios, porém, não divulgaram detalhes do estudo e, por isso, especialistas pedem cautela – o trabalho ainda não passou pela revisão de pares da comunidade acadêmica nem foi publicado em revista científica. Por décadas, as vacinas contra o câncer têm sido um dos caminhos mais promissores no tratamento da doença. A tecnologia de mRNA foi fundamental para o desenvolvimento rápido de vacinas durante a pandemia de covid-19. A notícia fez com que as ações da Moderna disparassem 176%. As da Merck subiram 12%, chegando a US$ 150. Política: Lobby de amiga de Lulinha previa lucro de 20% em contrato enviado a Marcola Metrópole: Com donos mortos, 8,4 mil armas têm destino incerto no País Economia: Casas Bahia deve reintegrar demitidos, determina Justiça Cultura: Madonna lidera em indicações para o Music Video AwardsSee omnystudio.com/listener for privacy information.

Plus: Target's second-quarter sales suggest the retailer's turnaround is working. And Cantor Fitzgerald plans to give its hedge-fund clients access to Kalshi's prediction markets. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The U.S. Treasury is "at least" doubling debt buybacks for longer-dated nominal coupon securities, causing a surge in fixed income activity after yields hit highs not seen in years. Kevin Hincks explains why the headline is so significant for bonds and beyond. He turns to global movers tied to the U.S.-Iran war after the United Arab Emirates cut off trade with Iran. In equities, Kevin discusses the massive move in Moderna (MRNA) shares after it and Merck (MRK) announced positive phase 3 results for a melanoma vaccine. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Featured Wellness Resource: Exodus Strong Explore Exodus Strong, a faith-centered wellness company offering red and near-infrared light therapy products including full-body mats, masks, wands, belts and other at-home devices, along with molecular hydrogen and botanical supplements, frequency-based wellness products, and complete Light Code wellness systems. If you're interested in exploring what Exodus Strong has to offer, please use Dr. Stephanie's link below. Purchases made through this affiliate link help support Conversations with a Chiropractor and allow us to keep bringing you new conversations each week. https://exodusstrong.com?a_aid=drstephanie In this episode of Conversations with a Chiropractor, Dr. Stephanie Wautier talks with Rob Rene, a faith-based wellness entrepreneur, author, podcast host, and founder of Exodus Strong. After surviving four near-death experiences, including a serious accident and a stage three melanoma diagnosis, Rob says his outlook on health, faith, and purpose changed completely. What followed was years of research into light, frequencies, nutrition, supplements, mindset, AI, and the ways he believes the body can be supported in healing. Rob shares the framework behind his upcoming book, Light Code, built around four pillars: light, frequencies, fuel, and faith. He explains how red and near-infrared light became part of his own recovery, why he became fascinated by frequency-based wellness, how his faith shaped the way he approached illness, and why he now believes health has to be looked at through more than one lens. Stephanie and Rob also talk about chronic fatigue, inflammation, molecular hydrogen, biblical ingredients used in Rob's supplements, personalized wellness, AI-assisted health research, the history of conventional and alternative medicine, and the importance of staying curious while taking responsibility for your own health. At the heart of the conversation is a message of hope. Rob puts it simply: if you have breath in your lungs today, there is still purpose in your life. Important Note This episode includes the guest's personal experiences, beliefs, interpretations of research, and opinions regarding cancer, frequency-based wellness, supplements, molecular hydrogen, red light therapy, healthcare history, media influence, and other health-related topics. Some claims discussed in this conversation are debated, emerging, or not established as medical consensus. This episode is intended for education and conversation only and should not be used for self-diagnosis or treatment. Please consult qualified healthcare professionals before making changes to cancer care, medications, supplements, light-based therapies, or other medical treatments. Listener Offer This episode of Conversations with a Chiropractor is supported by Lemongrove Oil. Use code DRSTEPHANIE at checkout for 10% off your order. https://www.lemongroveoil.com/ In This Episode Stephanie and Rob discuss Rob's four near-death experiences, his melanoma diagnosis, the four pillars of the Light Code system, red and near-infrared light, frequency-based wellness, chronic fatigue, nutrition and supplementation, molecular hydrogen, inflammation, faith and healing, the mind-body connection, self-advocacy, personalized wellness, AI and the future of health, and why Rob believes curiosity and hope can change the way people approach their health. Learn More About Rob Rene Exodus Strong: https://exodusstrong.com/ Biohackingville: https://biohackingville.com/ Upcoming Book: Light Code Rob also hosts a biohacking podcast and is developing additional wellness and research resources through Exodus Strong and Biohackingville. Conversations with a Chiropractor YouTube: http://www.youtube.com/@ConversationswithaChiro Facebook: https://www.facebook.com/wautierwellness Email: drstephaniewautier@yahoo.com Want to be a guest? Send Stephanie Wautier a message on PodMatch: https://www.podmatch.com/hostdetailpreview/drstephanie Credits Podcast production by Brand|Sound. Start your podcast journey by emailing brandsoundpodcasts@gmail.com. Chapters 00:00 Frequencies, Light, and the Human Body 02:38 Meet Rob Rene 04:41 The Light Code and Rob's Health Journey 07:25 Light, Sunlight, and Red Light Therapy 11:03 Becoming Your Own Health Advocate 12:30 Melanoma, Recovery, and Rob's Personal Experience 16:34 Understanding Frequencies 19:11 Frequency-Based Wellness and the Human Body 24:56 Chronic Fatigue and the Four Pillars 25:20 Fuel, Nutrition, and Supplementation 27:15 Molecular Hydrogen and Rob's Wellness Framework 28:10 Faith, Prayer, and the Mind-Body Connection 33:01 Alternative Medicine and Healthcare History 38:53 AI and the Future of Personalized Wellness 43:19 Hope, Purpose, and Rob's Message to Listeners 47:44 Where to Find Rob 49:13 Closing Thoughts  

Fiscalías de EE. UU. revisan casos de mexicanos muertos bajo custodia Volcadura en la México-Pachuca deja 25 personas lesionadas  Moderna dispara sus acciones 93% tras avance de su vacuna contra el melanomaMás información en nuestro podcast#grc

In today's episode, I sit down with James Templeton, founder of the Templeton Wellness Foundation and author of I Used to Have Cancer. After being diagnosed with Stage 4 melanoma at just 32 years old, James was faced with life-changing decisions. This conversation is for informational purposes only and is NOT medical advice. A portion of this interview has been removed from the YouTube version due to platform content policies. You can watch the full, unedited conversation on the Plus Side. Watch the full interview on the Plus Side: https://www.patreon.com/wakeupwithmiya Connect with James Templeton: https://www.templetonwellness.com If you enjoy these conversations, please subscribe, hit the notification bell, and if you're listening on Apple Podcasts or Spotify, I'd really appreciate it if you'd leave a positive review. It helps support the show and helps others find these conversations. BUY A COFFEE LINK Support the Show & Stay Connected:Buy Me a Coffee: https://buymeacoffee.com/sensiblehippie Join My Patreon for ad-free episodes & exclusive content:https://Patreon.com/WakeupwithMiya If you're joining Waiola – The Plus Side, please subscribe through a web browser (Safari or Chrome) instead of the Patreon app — it directly supports the show. Mahalo nui loa for supporting independent work and helping keep this platform growing. Shop my Amazon Storefront: https://www.amazon.com/shop/profile/amzn1.account.AGYOPCXXGH6MN5RVAKGQWVZUZLEA/list/26B87RB4FZ9W2?ref_=cm_sw_r_cp_ud_aipsflist_6BWRT43TH4MY2NM2XD6X Want to be on the show or suggest a guest?I'm looking for guests who can speak on human trafficking, the paranormal, occult symbolism, hidden history, spiritual warfare, ancient mysteries, and specific military stories involving covert operations, secret programs, psychological warfare, unexplained events, and firsthand accounts.Email me at: Miya@wakeupwithmiya.com Follow Me Online: Instagram: https://www.instagram.com/WakeupwithMiya Facebook: https://www.facebook.com/WakeupwithMiya Exclusive Discount! Shop at LVNTA: https://lvnta.com/lv_IcTq5EmoFKaZfJhTiSUse code OHANA for 20% off! Listen on Your Favorite Platform: Spotify, Apple Podcasts, YouTube, and everywhere podcasts are available! RATE & REVIEW:Apple: https://podcasts.apple.com/us/podcast/wake-up-with-miya/id1627169850Spotify: https://open.spotify.com/show/0UYrXCgma1lJYzf8glnAxyMusic Credits: Beginning: "Echoes in the Shadows" - DKEnd Music: “Crazy” - EkoBecome a supporter of this podcast: https://www.spreaker.com/podcast/wake-up-with-miya--6339129/support.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

In today's episode, we spoke with Marlana M. Orloff, MD. Dr Orloff is the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. In our exclusive interview, Dr Orloff discussed the distinct biology of uveal melanoma and why it has historically resisted systemic treatment. Unlike cutaneous melanoma, which carries a high tumor mutational burden and responds robustly to immune checkpoint inhibitors, uveal melanoma sits at the opposite end of the spectrum with low mutational burden, a predominantly liver-metastatic pattern, and an immune-tolerant microenvironment that renders traditional immunotherapy largely ineffective.She provided context on the treatment landscape for patients with HLA-A*02:01–negative metastatic uveal melanoma prior to the phase 2/3 OptimUM-02 trial (NCT05987332), noting that this population had limited options: liver-directed therapies such as percutaneous hepatic perfusion, off-label immune checkpoint inhibitor combinations, or clinical trial enrollment.Dr Orloff then walked through the design and efficacy findings of the trial, which evaluated the combination of darovasertib, an oral PKC inhibitor, plus crizotinib (Xalkori), a MET inhibitor, vs investigator's choice in treatment-naive, HLA-A*02:01–negative patients. The combination demonstrated a median progression-free survival of 6.9 months vs 3.1 months with investigator's choice, with an objective response rate of 37.1% compared with under 5.8% in the control arm. She highlighted the clinical significance of the complete responses observed while noting that overall survival data from the phase 3 portion of the trial remain pending.The discussion also addressed the growing complexity of treatment sequencing as more options emerge, including tebentafusp-tebn (Kimmtrak) for HLA-A*02:01–positive patients, liver-directed and combination approaches, and the investigational TCR-engineered T-cell therapy anzutresgene autoleucel targeting PRAME. Dr Orloff emphasized that in the absence of head-to-head comparisons, sequencing decisions will increasingly be shaped by patient logistics, toxicity profiles, and access to specialized treatment centers.

Connect with us via text! In this episode, the DERMASCOPE in-house aesthetician team explores the growing culture of prevention, longevity, and beauty optimization, including a promising personalized mRNA vaccine for melanoma recurrence and what it could signal for the future of skin cancer prevention, the booming longevity movement, and the role aesthetics plays in proactive wellness. Plus, they unpack the rising cost of pre-wedding beauty prep, questioning why so many are willing to spend thousands – and sometimes go into debt – to look their best for one day. Be sure to follow us on social media and your favorite podcast listening platforms for the inside scoop on the current events affecting the aesthetics industry! Follow DERMASCOPE:Instagram: @dermascopeFacebook: facebook.com/dermascopePinterest: @dermascopeTikTok: @dermascope                                                                                                 YouTube: youtube.com/@dermascopeFollow Elizabeth & LoniceElizabeth Brasher Instagram: @theskingalLonice Stoker Instagram: @lacedbylonicespaAdditional Links:Visit our website.Learn more about this podcast.Subscribe to the magazine.Read the July 2026 issue.Read the 2026 P&E Guide.

Sunspots usually stay flat and stable over time, while skin cancer often changes shape, color, texture, or sensation as abnormal cells grow and spread Melanoma warning signs follow the ABCDE rule: asymmetry, irregular borders, uneven color, larger diameter, and evolution over time, giving you a simple way to check your own skin each month Many sunspots contain lipofuscin, a waste pigment that researchers believe may form when linoleic acid from seed oils oxidizes in the presence of excess iron and sunlight Elevated ferritin and GGT levels have been associated with higher oxidative stress, which some researchers suggest may be reflected in the skin Lowering seed oil intake, reducing excess iron, using sunlight strategically, and acting quickly when a spot changes may help reduce oxidative stress on the skin and support earlier detection of changes

HEALTH NEWS   Melatonin may safely reduce chronic musculoskeletal pain, study finds Study: Nordic Walking Reduces Depression Symptoms Within Weeks Connection or compulsion: How smartphones can deepen depression in older adults This Popular Workout Supplement May Give Cancer Immunotherapy a Big Boost Probiotic metabolite found to suppress melanoma tumor growth in mice   Melatonin may safely reduce chronic musculoskeletal pain, study finds University of Sydney, June 30 2026 (News-Medical) A sleep supplement widely used to treat insomnia could help reduce reliance on some of the most common and potentially harmful pain medications, new research from the University of Sydney suggests.  Published in PAIN, the study found melatonin can reduce chronic musculoskeletal pain with effects in a similar range to medications such as opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.  The study analyzed data from 2028 adults across 23 randomised controlled trials conducted in countries including the United States, Russia, Brazil, Egypt and China. Participants included people with conditions such as low back pain, osteoarthritis and fibromyalgia, as well as those recovering from surgeries including joint replacements and spinal procedures.  On average, the study found that melatonin reduced pain by around nine points on a 0-100 scale, with the most rigorous trials showing reductions closer to 10 points, a similar magnitude to widely used pain medications. Across the trials, the dose and timing of melatonin varied depending on the condition and setting. For chronic musculoskeletal pain, doses typically ranged from 3 to 10 mg, with 3 mg per day the most commonly used. For postoperative pain, doses ranged from 1 to 10 mg, with 5 to 6 mg most common. Melatonin was generally taken at bedtime or up to one hour before sleep.     Study: Nordic Walking Reduces Depression Symptoms Within Weeks Université Grenoble Alpes (France), July 1 2026 (Natural News)   A randomized controlled trial published in the Journal of Affective Disorders found that supervised Nordic walking significantly reduced depression symptoms in adults with moderate to severe depression. The most pronounced improvements occurred within the first five weeks of the 10-week program, according to researchers. The study enrolled 64 adults, with 48 assigned to Nordic walking and 16 to a non-active control group.   The findings challenge the commonly cited three-month timeframe for exercise benefits on depression. A secondary analysis examined whether participants with severe depression responded differently than those with moderate symptoms. According to the study, Nordic walking is a low-impact activity that engages the upper and lower body using poles, similar to cross-country skiing. The Nordic walking group showed significantly greater reductions in depression symptoms compared to the control group over the full 10 weeks. The largest reduction occurred from baseline to week five, with a large effect size; improvements from week five to week ten were smaller and not statistically significant. Participants with severe depression at baseline experienced even larger and faster improvements in the first five weeks, according to the secondary analysis.   Connection or compulsion: How smartphones can deepen depression in older adults Rutgers University, July 1 2026 (Eurekalert)   Compulsive smartphone habits in older adults can be linked to a higher risk of depression, according to a study led by a Rutgers researcher.  Researchers said their findings raised concerns that technology widely promoted to build connections can instead deepen late-life isolation: While mobile devices can be invaluable lifelines, their impact on mental health depends heavily on the way people use them. A critical distinction, the researchers said, is whether someone uses technology to actively engage with the world or to withdraw. The study, published in JMIR Aging, drew on survey responses from 2,585 adults ages 60 and older living in 87 communities. Researchers collected health and demographic information, including age, gender, marital status, education and income, and measured depressive symptoms with a screening tool commonly used with older adults. Limited social participation emerged as the strongest predictor of depression, followed closely by smartphone addiction, defined as compulsive or excessive use that disrupts daily functioning. Problematic phone reliance appeared in nearly all cases of clinical depression, with older adults who rarely used interactive communication features facing the greatest risk. Another high-risk pattern emerged among older adults of both sexes: Those with higher incomes and education levels who suffered from smartphone addiction were more prone to clinical depression. This finding suggests that wealth, education, and technology access fail to protect against loneliness when screen time replaces real-world connections.   This Popular Workout Supplement May Give Cancer Immunotherapy a Big Boost University of California at Los Angeles, July 1, 2026 (SciTech Daily) Creatine, a supplement widely used by athletes and bodybuilders, may also strengthen the immune system's ability to fight cancer, according to new research from UCLA. Previous findings from the same research team show that creatine boosts the activity of killer T cells, which destroy cancer cells. The new research found that creatine also supports dendritic cells, the immune cells responsible for detecting tumor material and activating killer T cells to launch an attack. Although many approved cancer immunotherapies target killer T cells, only about 20% to 40% of patients benefit from these treatments. Enhancing dendritic cells, which prepare and activate T cells, could improve the effectiveness of immunotherapy for more people. The researchers found that dendritic cells inside tumors produced much higher levels of the gene responsible for the creatine transporter, the protein that moves creatine into cells, than dendritic cells found in healthy tissue. They investigated whether increasing creatine could improve dendritic cell performance. Daily creatine injections in mouse models of melanoma slowed tumor growth while increasing both the number and activity of dendritic cells within tumors. The treated dendritic cells also released more chemical signals that attracted additional immune cells to the tumor.     Probiotic metabolite found to suppress melanoma tumor growth in mice Southern Medical University (China), June 30 2026 (News-Medical)   Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to respond or eventually develop resistance. The tumor microenvironment and the gut microbiome are increasingly recognized as critical determinants of immunotherapy outcomes. Melanoma patients often show reduced levels of beneficial gut bacteria, including Bifidobacterium, and lower microbial diversity. Researchers have discovered that Bifidobacterium animalis—a probiotic commonly found in fermented dairy products—produces mannose, which activates CD8⁺ T cells and suppresses melanoma progression in mouse models. The study reveals a novel gut-microbiome-immune axis that could lead to new adjuvant strategies for melanoma immunotherapy.   When given orally to mice with melanoma tumors, the bacterium significantly reduced tumor volume and weight—without ever colonizing the tumor tissue itself, indicating that its effects were mediated entirely through secreted metabolites. Using size fractionation and metabolomics, the team identified mannose as the key bioactive molecule—a small, non-protein compound under 3 kilodaltons. In mice, drinking water supplemented with 1% mannose replicated the anti-tumor effects of the live probiotic, increasing tumor-infiltrating CD8⁺ T cells and boosting their production of killer molecules like granzyme B (GZMB), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).

There's a viral social media post claiming that you're 300% more likely to develop skin cancer when you use sunscreen. What's the truth? Is sunscreen safe to use? In this episode Doctor Motley breaks down the research, and brings a new lens to the debate: what did ancient cultures do for skin health? Here's what you'll learn in this episode: *Research has found chemicals in your sunscreen like oxybenzone can affect your estrogen and testosterone levels and block Vitamin D, - which is an important hormone, not just a vitamin! - plus some healthy sunscreen ingredients to look for. *What is the "sunscreen paradox" *Why heavily sun-protected, indoor populations showed higher melanoma rates in UK research *How to build a solar callus: the traditional method of safe, gradual sun exposure that builds your skin's natural protection *How to create a healthy skin protocol this summer: Develop early morning sun exposure over time, plus take good vitamins (like B3), minerals and herbs! *Skin protection from a TCM perspective: In Chinese Medicine, the strength of the skin is connected to the strength of your lungs. Find out how to protect your skin with TCM herbs. Research: FDA Findings:https://jamanetwork.com/journals/jama/fullarticle/2733085#google_vignette The Sunscreen Paradox https://www.sciencedaily.com/releases/2023/10/231027110724.htm Chemicals in Sunscreen: https://www.ewg.org/sunscreen/report/the-trouble-with-sunscreen-chemicals/ Vitamin B Study: https://www.nejm.org/doi/full/10.1056/NEJMoa1506197 https://doi.org/10.3390/nu17071240 ------  Want more of The Ancient Health Podcast? Subscribe to the YouTube channel. Follow Doctor Motley Instagram Facebook Website ------  *You can get cell support in gummy form: Mitopure now starts at $79, when you go to timeline.com/DRMOTLEY. *Join Doctor Motley's newsletter for TCM insights and regular podcast updates: https://www.doctormotley.com/ *Do you have a ton more in-depth questions for Doctor Motley? Check out his course on emotions and the body in his membership. You'll find other courses full of his expertise and clinical wisdom, plus bring all your questions to his weekly lives! To try risk-free for 15 days click here: https://www.doctormotley.com/15 ------ DISCLAIMER Please remember that the information shared in this podcast is for education purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice.   No doctor-patient relationship is formed through this podcast, and the use of information here or materials linked from this podcast is at your own risk.   The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult with your healthcare provider before making any changes to your health regimen, and do not disregard or delay seeking medical advice for any condition you may have.

Skin Cancer Prevention, Anti-Aging Biohacking, and the Melanoma Detection Gap Most dermatologists are missing melanoma, and a board-certified skin cancer specialist explains exactly why, and what to do about it. This episode covers the detection tool that finds 10 times more melanomas, the real truth about sunscreen chemicals, the biohacking peptide that can hide cancer on your skin, and the cheap anti-aging drug that most people have never tried. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. Michael Christopher, a board-certified dermatologist and expert dermoscopist recognized for his work in early melanoma detection. Through consistent, evidence-based use of dermoscopy, he identifies between 150 and 215 melanomas annually, far exceeding national and state averages and exposing a critical gap in standard skin cancer screening. Dr. Christopher speaks regularly on prevention, early detection, and systemic failures in dermatology training across health, wellness, and longevity-focused media, and has made it his mission to change the standard of care before more people die from a cancer that is almost always curable when caught early. Dave and Dr. Christopher break down why a standard skin exam with no additional tools is essentially a guess, how dermoscopy changes everything, and why most dermatologists who claim to use it actually cannot interpret what they see. They get into the real risk factors for rising melanoma rates, what sunscreen labels are not telling you, and how melanotan and other biohacking peptides interact with your skin cancer risk in ways that matter. They also cover tretinoin as one of the most evidence-backed anti-aging and skin optimization tools available, how red lighttherapy supports mitochondria function and skin rejuvenation, and what parents should know about protecting their kids' skin for long-term longevity You'll Learn: Why most dermatologists miss melanoma and what the detection gap actually looks like What dermoscopy is, how it works, and why you should ask for it by name How melanoma survival drops from 99% at stage one to 73% at stage three What the Prop 65 cancer warning on most pharmacy sunscreens actually means Why visible light can darken your skin even when you wear sunscreen How melanotan activates melanocortin receptors and why that may affect melanoma risk What Retin-A does to collagen, the epidermis, and long-term skin aging How AI is entering dermoscopy and where it still falls short The right concentration of tretinoin to start with and how to get through the adjustment period What parents should do now to protect their kids from melanoma later Thank you to our sponsors! -Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com.-Viome | Check it out at viome.com and use code 10DAVE for 10% off. It's time to stop guessing and start knowing your body.-Timeline | Go to timeline.com/dave and you'll get an additional 20% off your first month-Redmond Real - Leaf Toothpaste | Go to https://redmond.com/asprey and use code ASPREY for 15% off your first order.Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Michael Christopher, Dr. Michael Christopher, melanoma detection, dermoscopy, dermatoscope, skin cancer screening, melanoma prevention, early melanoma detection, skin cancer biohacking, sunscreen toxins, Prop 65 sunscreen, mineral sunscreen, zinc oxide, titanium dioxide, melanotan, melanocortin, skin aging, anti-aging, tretinoin, Retin-A, retinol, skin rejuvenation, collagen, red light therapy, mitochondria, UV exposure, UVB light, skin cancer longevity, melanoma survival rate, squamous cell carcinoma, functional medicine, human performance, longevity, biohacking, supplements, skin optimization, dermoscopy AI, skin cancer AI, visible light tanning, omega-6 sunburn, astaxanthin, skin health, melanoma staging, skin exam, skin cancer prevention Resources: • Learn More About Dr. Christopher's Work At: https://www.instagram.com/michael_christopher_md/ • Purchase Dr. Fotuhi's New Book The Invincible Brain: https://a.co/d/0iHCgPpL • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 – Trailer 1:41 – Guest Introduction 3:59 – Dermatoscope Explained 12:27 – Melanoma Rising: Why 16:57 – Melanotan & Sun Risk 21:14 – Melanoma & Longevity 22:31 – Stage 1 vs Stage 3 26:05 – Retin-A Deep Dive 38:53 – Loose Skin Solutions 41:26 – Kids' Skin Health See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join the Behind the Knife Surgical Oncology Team as we discuss clinical challenges through case-based examples including the diagnosis, workup, and management of patients with cutaneous melanoma. Learning Objectives:In this episode, we review the workup and management of patients with cutaneous melanoma and both microscopic and macroscopic nodal disease. References used in the making of this episode: Reijers, I.L.M., Menzies, A.M., van Akkooi, A.C.J. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 28, 1178–1188 (2022). https://doi.org/10.1038/s41591-022-01851-x Christian U. Blank et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. J Clin Oncol 42, LBA2-LBA2(2024). DOI:10.1200/JCO.2024.42.17_suppl.LBA2 Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211-2222. doi:10.1056/NEJMoa1613210   https://pubmed.ncbi.nlm.nih.gov/28591523/ National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 1.2026. Accessed April 8, 2026. NCCN Guidelines PDF   Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US